CRISPR Therapeutics AG (CRSP) Convertible Debt (2015)

CRISPR Therapeutics AG has disclosed Convertible Debt across 1 years of filings, most recently posting $38.3 million for Q4 2015.

• In Q4 2015, Convertible Debt changed N/A year-over-year to $38.3 million; the TTM figure through Dec 2015 stood at $38.3 million (changed N/A YoY), while the FY2015 annual figure was $38.3 million, changed N/A from the prior year.
• Convertible Debt came in at $38.3 million for Q4 2015 at CRISPR Therapeutics AG.
• In the past five years, Convertible Debt ranged from a high of $38.3 million in Q4 2015 to a low of $38.3 million in Q4 2015.